The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
APO2 ligand: a novel lethal weapon against malignant glioma?
Abstract
APO2L (TRAIL) is a novel CD95L (Fas/APO‐1‐L) homologous cytotoxic cytokine that interacts with various receptors which transmit (DR4, DR5) or inhibit (DcR1, DcR2) an apoptotic signal. Here, we report that human glioma cell lines preferentially express mRNAs for agonistic death receptors DR4 (8/12) and DR5 (11/12) rather than the death‐inhibitory decoy receptors DcR1 (4/12) and DcR2 (2/12). Ten of 12 cell lines are susceptible to APO2L‐induced apoptosis. The resistant cell lines, U138MG and U373MG, are cross‐resistant to CD95L‐induced apoptosis. Similar to CD95L‐induced apoptosis, APO2L‐induced apoptosis is inhibited by ectopic expression of the caspase inhibitor, crm‐A, or of bcl‐2, or by coexposure to the corticosteroid, dexamethasone, or the lipoxygenase inhibitor, nordihydroguaretic acid. There is no correlation between p53 genetic status of the cell lines and their susceptibility to APO2L‐induced apoptosis, but the latter is moderately enhanced by ectopic expression of wild‐type p53. APO2L targeting may be a promising approach for selectively targeting apoptosis to human malignant glioma cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881
Cited by
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Self-citationTargeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
Self-citationHerbst, R. S., Eckhardt, S. G., Kurzrock, R., Ebbinghaus, S., O'Dwyer, P. J., Gordon, M. S., Novotny, W., Goldwasser, M. A., Tohnya, T. M., Lum, B. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1991 · Cited by 446
Self-citationAshkenazi, A., Holland, P., & Eckhardt, S. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7198 · Cited by 421
Self-citationCorsten, M. F., Miranda, R., Kasmieh, R., Krichevsky, A. M., Weissleder, R., & Shah, K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1045 · Cited by 406
Metadata
- Authors
- Rieger, J., Naumann, U., Glaser, T., Ashkenazi, A., & Weller, M.
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 1998-05
- Volume
- 427
- Issue
- 1
- Pages
- 124-128
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- OpenAlex
- W2055905844
- Cited by
- 189
- References
- 2
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: APO2 ligand: a novel lethal weapon against malignant glioma? https://app.cochat.ai/papers/10.1016/s0014-5793(98)00409-8
- The paper
- Rieger, J., Naumann, U., Glaser, T., Ashkenazi, A., & Weller, M. (1998). APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Letters. https://doi.org/10.1016/s0014-5793(98)00409-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.